C Rad : The Nomination Committee's revised proposal before the Annual General Meeting 2024

The Nomination Committee of C-RAD AB (publ) has decided to propose that the Annual General Meeting 2024 approves the following revised proposals regarding the number of Board members and election of the Board of Directors.

The Nomination Committee proposes that the Board of Directors should consist of six Board members elected by the General Meeting, without Deputies, for the period until the next Annual General Meeting.

The Nomination Committee proposes re-election of Jenny Rosberg, David Sjöström, Kristina Willgård, Susanne Ekblom and Peter Simonsbacka, and election of Mats Thorén as Board members for the period until the next Annual General Meeting. Kristina Willgård is proposed to be re-elected as Chair of the Board of Directors for the period until the next Annual General Meeting.

Mats Thorén, born in 1971, has solid experience from the financial market, primarily focused on the life science sector as an analyst and in corporate finance. He is CEO and Board member of the company Vixco Capital AB as well as Board member of Arcoma AB, Arcoma Incentive AB, Herantis Pharma Oyj, FluoGuide A/S and Xbrane Biopharma AB as well as Deputy of Eggelbertus Holding AB and has previous experience as a Board member of C-RAD AB (publ) and Nalka Life Science AB. Mats Thorén studied at Stockholm School of Economics and studied medicine at Karolinska Institutet in Stockholm. Mats Thorén is independent in relation to the company and company management as well as independent in relation to the company's major shareholders and he owns no shares in the company.

Information concerning the current Board members who are proposed for re-election is available on the company's website, www.c-rad.com

As the Nomination Committee's revised proposal includes six Board members instead of the previous five Board members, the total Board fee amounts to a total of SEK 1,720,000, in accordance with the Nomination Committee's proposal.

The Annual General Meeting will be held on May 15, 2024.

For further information:

Cecilia de Leeuw, CEO, +46 (0)795 85 66 77, investors@c-rad.com

About C-RAD

C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.

C-RAD. Inspiring excellence in cancer treatment.

C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit http://www.c-rad.com